| Accounting at Biovail - Revised (Spreadsheet) |
| 作者姓名：Mary Gillett; Mary-Jane Mastrandrea |
| 商品類型： | 商品編號：7B09B004 |
| 出版日期：2010/08/16 | 內容長度：200 頁 |
Spreadsheet for product 9B09B004.
|
| Measuring Impairment at Dofasco (Spreadsheet) |
| 作者姓名：Mary Gillett; Mary-Jane Mastrandrea |
| 商品類型： | 商品編號：7B09B017 |
| 出版日期：2010/08/16 | 內容長度：197 頁 |
Spreadsheet for product 9B09B017.
|
| Measuring Impairment at Dofasco |
| 作者姓名：Mary Gillett; Mary-Jane Mastrandrea |
| 商品類型：Case (Pub Mat) | 商品編號：9B09B017 |
| 出版日期：2010/01/25 | 內容長度：21 頁 |
In December 2008, the ArcelorMittal Dofasco (Dofasco) accounting team was facing a significant challenge. In the past few years, Dofasco had undergone significant ownership changes, and when the firm had first been acquired the market had placed a premium share value on the Dofasco subsidiary. In light of a recent economic downturn, the accounting team was required to reassess the values assigned to the subsidiary's net assets. Dismal forecasted .....more
|
| Accounting at Biovail - Revised |
| 作者姓名：Mary Gillett; Mary-Jane Mastrandrea;Jessica Frisch |
| 商品類型：Case (Pub Mat) | 商品編號：9B09B004 |
| 出版日期：2009/07/01 | 內容長度：19 頁 |
Biovail was a large international pharmaceutical company with reported revenues of $788 million. Banc of America has issued a research report which indicates that Biovail Corporation's financial statements raised a number of issues that warrant caution for investors, and as a result, Biovail's stock was given a sell rating by Banc of America. A member of Biovail's audit committee is preparing for an upcoming audit meeting and considers .....more
|
| Accounting at Biovail - Revised - Teaching Note |
| 作者姓名：Mary Gillett; Mary-Jane Mastrandrea |
| 商品類型： | 商品編號：8B09B04 |
| 出版日期：2009/05/29 | 內容長度：12 頁 |
Teaching for product 9B09B004.
|
| Accounting for Financial Instruments |
| 作者姓名：Darroch A. Robertson; Mary Heisz; Mary-Jane Mastrandrea |
| 商品類型：Note | 商品編號：9B07B014 |
| 出版日期：2008/01/31 | 內容長度：12 頁 |
This note provides an overview of the Canadian accounting standards for financial instruments. Classification, valuation and disclosure are discussed.
|